Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2019
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
gptkb:N03AX39
|
| gptkbp:brand |
gptkb:Xcopri
Ontozry |
| gptkbp:CASNumber |
1354632-67-7
|
| gptkbp:chemicalFormula |
C16H15Cl2N3O
|
| gptkbp:drugClass |
antiepileptic drug
|
| gptkbp:genericName |
gptkb:cenobamate
|
| https://www.w3.org/2000/01/rdf-schema#label |
Xcopri
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
SK Life Science
|
| gptkbp:mechanismOfAction |
modulation of voltage-gated sodium channels
positive allosteric modulation of GABAA receptors |
| gptkbp:pregnancyCategory |
Not assigned
|
| gptkbp:prescriptionStatus |
Rx only
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
dizziness fatigue headache drowsiness double vision |
| gptkbp:usedFor |
treatment of partial-onset seizures
|
| gptkbp:bfsParent |
gptkb:Cenobamate
|
| gptkbp:bfsLayer |
7
|